Skip to main content

Clinical Trials Using ATR Inhibitor

Review the clinical trials studying atr inhibitor on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Status: Active
Location: 109 locations
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Status: Active
Location: 22 locations
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Status: Active
Location: 15 locations
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Status: Active
Location: 13 locations
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Status: Active
Location: 11 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Status: Active
Location: 10 locations
Testing the Combination of two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Status: Active
Location: 5 locations
Ceralasertib with or without Olaparib or Durvalumab in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 4 locations
Avelumab with M1774 for the Treatment of Patients with ARID1A-Mutated Recurrent Endometrial Cancer who have Received Prior Immunotherapy
Status: Active
Location: 2 locations
Olaparib with Ceralasertib for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients with Non-Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: 193 locations